Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making.
GBM
next-generation sequencing
targeted therapy
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
01 07 2022
01 07 2022
Historique:
pubmed:
9
12
2021
medline:
8
7
2022
entrez:
8
12
2021
Statut:
ppublish
Résumé
Targeted gene NGS testing is available through many academic institutions and commercial entities and is increasingly incorporated in practice guidelines for glioblastoma (GBM). This single-center retrospective study aimed to evaluate the clinical utility of incorporating NGS results in the management of GBM patients at a clinical trials-focused academic center. We identified 1011 consecutive adult patients with pathologically confirmed GBM (IDHwt or IDHmut) who had somatic tumor sequencing (Oncopanel, ~500 cancer gene panel) at DFCI from 2013-2019. Clinical records of all IDHwt GBM patients were reviewed to capture clinical trial enrollment and off-label targeted therapy use based on NGS results. Of the 557 IDHwt GBM patients with sequencing, 182 entered clinical trials at diagnosis (32.7%) and 213 (38.2%) entered after recurrence. Sequencing results for 130 patients (23.3%) were utilized for clinical trial enrollment for either targeted therapy indications (6.9 % upfront and 27.7% at recurrent clinical trials and 3.1% for off-label targeted therapy) or exploratory studies (55.4% upfront and 6.9% recurrent clinical trials). Median overall survival was 20.1 months with no survival difference seen between patients enrolled in clinical trials compared to those who were not, in a posthoc analysis. While NGS testing has become essential for improved molecular diagnostics, our study illustrates that targeted gene panels remain underutilized for selecting therapy in GBM-IDHwt. Targeted therapy and clinical trial design remain to be improved to help leverage the potential of NGS in clinical care.
Sections du résumé
BACKGROUND
Targeted gene NGS testing is available through many academic institutions and commercial entities and is increasingly incorporated in practice guidelines for glioblastoma (GBM). This single-center retrospective study aimed to evaluate the clinical utility of incorporating NGS results in the management of GBM patients at a clinical trials-focused academic center.
METHODS
We identified 1011 consecutive adult patients with pathologically confirmed GBM (IDHwt or IDHmut) who had somatic tumor sequencing (Oncopanel, ~500 cancer gene panel) at DFCI from 2013-2019. Clinical records of all IDHwt GBM patients were reviewed to capture clinical trial enrollment and off-label targeted therapy use based on NGS results.
RESULTS
Of the 557 IDHwt GBM patients with sequencing, 182 entered clinical trials at diagnosis (32.7%) and 213 (38.2%) entered after recurrence. Sequencing results for 130 patients (23.3%) were utilized for clinical trial enrollment for either targeted therapy indications (6.9 % upfront and 27.7% at recurrent clinical trials and 3.1% for off-label targeted therapy) or exploratory studies (55.4% upfront and 6.9% recurrent clinical trials). Median overall survival was 20.1 months with no survival difference seen between patients enrolled in clinical trials compared to those who were not, in a posthoc analysis.
CONCLUSIONS
While NGS testing has become essential for improved molecular diagnostics, our study illustrates that targeted gene panels remain underutilized for selecting therapy in GBM-IDHwt. Targeted therapy and clinical trial design remain to be improved to help leverage the potential of NGS in clinical care.
Identifiants
pubmed: 34878541
pii: 6456497
doi: 10.1093/neuonc/noab282
pmc: PMC9248387
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1140-1149Subventions
Organisme : NINDS NIH HHS
ID : K08 NS101091
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS116144
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
J Clin Neurosci. 2013 Jun;20(6):783-9
pubmed: 23639619
Neuro Oncol. 2021 Aug 2;23(8):1215-1217
pubmed: 34185090
Lancet Oncol. 2012 Jul;13(7):707-15
pubmed: 22578793
Neuro Oncol. 2019 Dec 17;21(12):1498-1508
pubmed: 31276167
Neuro Oncol. 2020 Aug 17;22(8):1073-1113
pubmed: 32328653
Nature. 2020 Apr;580(7804):517-523
pubmed: 32322066
Brain Pathol. 2020 Sep;30(5):863-866
pubmed: 32502305
J Clin Neurosci. 2012 Nov;19(11):1530-4
pubmed: 22989795
Acta Neuropathol. 2016 Jun;131(6):903-10
pubmed: 26671409
Neuro Oncol. 2021 Oct 1;23(10):1789-1797
pubmed: 33693781
Arch Pathol Lab Med. 2017 Jun;141(6):751-758
pubmed: 28557599
JAMA Oncol. 2020 Dec 1;6(12):1972-1974
pubmed: 33090181
Acta Neuropathol. 2018 Mar;135(3):481-484
pubmed: 29372318
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Nature. 2019 Dec;576(7785):112-120
pubmed: 31748746
Neuro Oncol. 2019 Feb 14;21(2):167-178
pubmed: 30189035
JAMA Oncol. 2018 Aug 1;4(8):1093-1098
pubmed: 29710180
JCO Precis Oncol. 2019 Mar 27;3:
pubmed: 32914038
J Clin Oncol. 2020 Jan 1;38(1):81-99
pubmed: 31743054
Brain Pathol. 2020 Jul;30(4):844-856
pubmed: 32307792
Lancet Oncol. 2016 Feb;17(2):e81-e86
pubmed: 26868357
JAMA Oncol. 2021 May 1;7(5):675-676
pubmed: 33475680
JCI Insight. 2016 Nov 17;1(19):e87062
pubmed: 27882345
J Mol Diagn. 2017 Jan;19(1):4-23
pubmed: 27993330
Acta Neuropathol. 2018 Nov;136(5):805-810
pubmed: 30259105
J Neurooncol. 2021 May;152(3):515-522
pubmed: 33646525
Front Oncol. 2014 Jul 21;4:126
pubmed: 25101239
Clin Cancer Res. 2018 Feb 15;24(4):737-743
pubmed: 28814435
Oncotarget. 2016 Aug 9;7(32):52493-52516
pubmed: 27191992
Nature. 2019 Jan;565(7741):654-658
pubmed: 30675060
Acta Neuropathol. 2018 Apr;135(4):639-642
pubmed: 29497819
Nat Rev Neurol. 2021 Jan;17(1):7-22
pubmed: 33106619
N Engl J Med. 2017 Mar 16;376(11):1027-1037
pubmed: 28296618
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Acta Neuropathol. 2020 Mar;139(3):603-608
pubmed: 31996992
Surg Pathol Clin. 2020 Jun;13(2):209-215
pubmed: 32389262
Acta Neuropathol. 2019 Apr;137(4):683-687
pubmed: 30848347
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931